New hope for kids with rare cancers: expanded access to DFMO drug
NCT ID NCT03581240
First seen Feb 22, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study offers expanded access to the drug DFMO for children and young adults (ages 0-30) with rare, relapsed tumors like neuroblastoma and medulloblastoma. The drug targets tumors with specific genetic markers (LIN28, MYCN, or ODC). The goal is to provide treatment when no other options are available, aiming to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
AVAILABLEHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.